TAK and 4502:JP Related Headlines

Go Back

May 26, 2026 06:19AM Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY7,900 at Citi

May 14, 2026 06:28AM Takeda Pharmaceutical (4502:JP) (TAK) PT Lowered to JPY6,400 at Macquarie

Apr 8, 2026 09:35AM Bernstein SocGen Group Upgrades Takeda Pharmaceutical (4502:JP) (TAK) to Outperform

Apr 2, 2026 02:40AM Citi Upgrades Takeda Pharmaceutical (4502:JP) (TAK) to Buy

Mar 31, 2026 03:19AM Macquarie Reiterates Outperform Rating on Takeda Pharmaceutical (4502:JP) (TAK)

Mar 13, 2026 02:12AM Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY6,200 at Citi

Mar 12, 2026 05:18AM Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY6,700 at Nomura/Instinet

Feb 26, 2026 06:28AM Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY4,900 at JPMorgan

Jan 30, 2026 11:25AM Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY5,800 at CLSA

Jan 15, 2026 07:52AM Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY5,600 at BofA Securities

Jan 13, 2026 07:47AM Morgan Stanley Resumes Takeda Pharmaceutical (4502:JP) (TAK) at Overweight, 'Our second most preferred stock'

Oct 14, 2025 06:36AM Takeda Pharmaceutical (4502:JP) (TAK) PT Lowered to JPY5,000 at Macquarie

Sep 23, 2025 02:29AM Morgan Stanley Reiterates Overweight Rating on Takeda Pharmaceutical (4502:JP) (TAK)

Jun 12, 2025 06:37AM Takeda Pharmaceutical (4502:JP) (TAK) PT Lowered to JPY5,300 at Nomura/Instinet

TAK and 4502:JP Related Press Releases

Go Back

TAK and 4502:JP Related SEC Filings

Go Back